Search

3 result(s) for 'author#Mehrzad Mirzania' within BMC

1. Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

   Authors: Abolghasem Allahyari, Ali Ehsanpour, Behrouz Najafi, Nafseh Ansarinejad, Valiollah Mehrzad, Behjat Kalantari, Jahangir Raafat, Mojtaba Ghadiany, Farhad Shahi, Behrooz Gharib, Vahid Moazed, Adnan Khosravi, Mir Hossein Mirpour, Sina Salari, Seyedmohammadreza Mortazavizadeh, Amirabbas Nekoyi…

   Citation: BMC Cancer 2022 22:1348

   Content type: Correction Published on: 22 December 2022

   The original article was published in BMC Cancer 2022 22:960

   • View Full Text
   • View PDF

2. Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

   Breast cancer is the most frequently diagnosed cancer and the leading reason for cancer-related death among women. Neoadjuvant treatment with dual-HER2 (human epidermal growth factor receptor 2) blockade has s...

   Authors: Abolghasem Allahyari, Ali Ehsanpour, Behrouz Najafi, Nafiseh Ansarinejad, Valiollah Mehrzad, Behjat Kalantari, Jahangir Raafat, Mojtaba Ghadiany, Farhad Shahi, Behrooz Gharib, Vahid Moazed, Adnan Khosravi, Mir Hossein Mirpour, Sina Salari, Seyedmohammadreza Mortazavizadeh, Amirabbas Nekoyi…

   Citation: BMC Cancer 2022 22:960

   Content type: Research Published on: 7 September 2022

   The Correction to this article has been published in BMC Cancer 2022 22:1348

   • View Full Text
   • View PDF

3. A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients

   This study compared efficacy and safety of TA4415V, a trastuzumab biosimilar, with reference trastuzumab in patients with human epidermal growth factor receptor 2–positive (HER2-positive) early-stage breast cance...

   Authors: Reza Safaei Nodehi, Behjat Kalantari, Jahangir Raafat, Nafiseh Ansarinejad, Vahid Moazed, Seyed Mohammad Reza Mortazavizadeh, Mehran Hosseinzadeh, Bayazid Ghaderi, Arash Jenabian, Mojtaba Qadyani, Shirin Haghighat, Abolghasem Allahyari, Mehrzad Mirzania, Mohammad Seghatoleslami, Mehrdad Payandeh, Afsaneh Alikhasi…

   Citation: BMC Pharmacology and Toxicology 2022 23:57

   Content type: Research Published on: 28 July 2022

   • View Full Text
   • View PDF